On Monday October 17, 2022, the U.S. Food and Drug Administration announced it has awarded 19 new grants and two new contracts totaling more than $38 million in funding over the next four years to support clinical trials, natural history …
Newly published data on tofersen shows success in treating SOD1-ALS
New results published this week provide further evidence that tofersen, a drug in development by Biogen, may be effective in slowing the progression of SOD1-ALS. As reported in the New England Journal of Medicine, the Phase 3 clinical trial (VALOR) …
FDA grants priority review for new SOD1-ALS treatment
The U.S. Food and Drug Administration (FDA) has accepted a New Drug Application for tofersen, a drug in development by Biogen for treatment of superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS) – and granted priority review for the application. …
New results show promise in treatment of SOD1-ALS
New results from the Phase 3 clinical trial of tofersen, a drug in development by Biogen, have shown promise in treatment of superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS). According to the 12-month data, earlier initiation of treatment with …
NU-9 Update: Experimental drug repairs upper motor neurons in mouse model
As connecting fibers between motor neurons, axons help deliver vital messages between the brain and the spinal cord. For people living with ALS, deteriorating axons cause that connection to break, contributing to paralysis and death. Early research on NU-9, an …
Research News from the Les Turner ALS Center at Northwestern Medicine
The 40+ research scientists at the Les Turner ALS Center at Northwestern Medicine investigate a wide range of biologic mechanisms in ALS basic research. We are pleased to announce the recent publication of three new research papers from some of …
Nearly $1 Million in ALS Grants Awarded in 2022
The Les Turner ALS Foundation is excited to announce nearly $1 million to be funded in 2022 for new research grants and clinic and endowment support to the Les Turner ALS Center at Northwestern Medicine! These discoveries would not have …
Response to NINDS Request for Information on ALS Strategic Plan
February 11, 2022 Dear NINDS, As we set our sights on shaping the strategic future of ALS research, we thank you for the opportunity to identify key research and priorities at NIH and beyond. We also recognize …
ALS News Today: New Directions in Research, Care Focus of Les Turner ALS Symposium
By Marta Figueiredo PhD | November 18, 2021 Recent findings and ongoing efforts to more fully understand the underlying molecular mechanisms of amyotrophic lateral sclerosis (ALS), and to identify new and better ways of helping patients were discussed at the 11th Annual Les Turner Symposium …
Les Turner ALS Symposium Celebrates Advances in Research and Patient Care
BY MELISSA ROHMAN ON NOV 4, 2021 Northwestern scientists and clinicians demonstrated their continued commitment to advancing knowledge and therapies for amyotrophic lateral sclerosis (ALS) during the 11th annual Les Turner Symposium on ALS. The virtual, daylong symposium featured scientific presentations highlighting the molecular …
